Evidence map›Paper›PMID 37324436›Full record

ArticleFrontiers in bioengineering and biotechnology2023

Tri-element nanozyme PtCuSe as an ingenious cascade catalytic machine for the amelioration of Parkinson's disease-like symptoms.

Hongdang Xu, Xin Ding, Lingrui Li, Qing Li, Zhiye Li, Hongqi Lin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Hongdang XuDepartment of Anesthesiology, Henan Provincial People's Hospital, People's Hospital of Henan University, Central China Fuwai Hospital, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Xin DingDepartment of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Lingrui LiThe Application Center for Precision Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Qing LiThe Application Center for Precision Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhiye LiThe Application Center for Precision Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Hongqi LinDepartment of Anesthesiology, Henan Provincial People's Hospital, People's Hospital of Henan University, Central China Fuwai Hospital, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Second Affiliated Hospital of Zhengzhou University · CNFirst Affiliated Hospital of Zhengzhou University · CNHenan Provincial People's Hospital · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD), as the second most common neurodegenerative disease after Alzheimer's, has become intractable with the increasing aging global population. The exploration of nanomedicine has broadened the opportunities for developing novel neuroprotective therapies. In particular, polymetallic functional nanomaterials have been widely used in the biomedicine field in recent years, exhibiting flexible and diversified functions and controllable properties. In this study, a tri-element nanozyme (PtCuSe nanozyme) has been developed with desirable CAT- and SOD-like activities for the cascade scavenging of reactive oxygen species (ROS). In particular, the nanozyme is suitable for relieving nerve cell damage by removing reactive oxygen species in cells and mitigating the behavioral and pathological symptoms in animal models of Parkinson's disease. Therefore, this ingenious tri-element nanozyme may have potential in the treatment of Parkinson's disease and other neurodegenerative diseases.

Indexed as

nanozymenerve cell damageParkinson’s diseasePtCuSereactive oxygen species

Identifiers

PMID37324436
PMCPMC10266212
OpenAlexW4378907626

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.